Navigation Links
Repligen Reports Fourth Quarter and Fiscal Year 2009 Financial Results
Date:6/11/2009

ical need. There are more than 300,000 MRI procedures conducted in the U.S. and Europe each year that could benefit from the use of RG1068.

RG2417 for Bipolar Disorder

We are currently enrolling a Phase 2b clinical trial of RG2417, an oral formulation of uridine, in patients with bipolar depression. This is a multi-center, randomized, double-blind, placebo-controlled clinical trial in which approximately 150 patients with bipolar depression will receive either RG2417 or a placebo twice a day for eight weeks. The study is designed to assess the safety and efficacy of RG2417 on the symptoms of depression as measured by the Montgomery-Asberg Depression Rating Scale (MADRS) and the Clinical Global Impression of Change in Bipolar Disorder scale (CGI-BP-C). The design of the ongoing study is based on the positive results of a Phase 2a study in which 83 patients received either RG2417 or a placebo twice a day for six weeks. Over the six-week treatment period, the study demonstrated a statistically significant improvement in the symptoms of depression in the patients receiving RG2417 when compared to placebo on the MADRS (p=0.01) and the CGI-BP-C (p=0.04). In March, Repligen exclusively licensed worldwide rights to a patent application from McLean Hospital for the use of uridine in the treatment of patients with bipolar disorder. If issued, the patent would remain in force until at least 2025. More than two million adults in the U.S. have bipolar disorder.

HDAC Inhibitors for Friedreich's Ataxia and Huntington's Disease

We are currently developing inhibitors of histone deacetylases (HDACs) for the treatment of inherited neurodegenerative diseases such as Friedreich's ataxia and Huntington's disease. Preclinical studies have shown that HDAC inhibitors have the potential to arrest disease progression in Friedreich's ataxia, a novel approach to treating this debilitating disease. We have identified sever
'/>"/>

SOURCE Repligen Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Repligen Announces Conference Call of Fourth Quarter and Fiscal Year 2009 Results
2. Repligen to Present at the Cowen and Company 29th Annual Healthcare Conference Monday, March 16th, 2:25 p.m. EDT
3. Repligen Reports Third Quarter Fiscal Year 2009 Financial Results
4. Repligen to Present at the BIO CEO & Investor Conference Monday, February 9th, 11:30 a.m. EST
5. Repligen Announces Conference Call of Third Quarter Fiscal Year 2009 Results
6. Repligen to Present at the Rodman & Renshaw 10th Annual Healthcare Conference Monday, November 10th, 4:55 p.m. EST
7. Repligen to Present at the 2008 UBS Global Life Sciences Conference Wednesday, September 24th, 1:00 p.m. EDT
8. Repligen Announces Publication of Positive Results with Proprietary HDAC Inhibitor in Huntingtons Disease Model
9. Repligen Receives Research Grants to Support Friedreichs Ataxia Development Program
10. Repligen Announces Conference Call of First Quarter Fiscal Year 2009 Results
11. Repligen Reports Fourth Quarter and Fiscal Year 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... (PRWEB) September 19, 2014 ... its potential to revolutionize the world has attracted ... corporations and small start-ups. The early years of ... projects largely due to the high risks involved, ... budgets earmarked for this evolving technology have been ...
(Date:9/19/2014)... , Sept. 19, 2014 Pfenex Inc. (NYSE ... development of high-value and difficult to manufacture proteins including ... at the 21 st Annual NewsMakers in the ... . Bertrand Liang , chief executive officer of ... programs and business strategy on Friday, September 26, 2014 ...
(Date:9/19/2014)... Dublin ... announced the addition of the  "Micro Market Monitor ... offering.       (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , , ... fastest-growing segments in the chromatography market. The market ... expected to reach $2.0 billion by 2019, at ...
(Date:9/18/2014)... TX (PRWEB) September 18, 2014 ... integrated urological and interventional radiology products and services, ... known as cryotherapy and cryoablation) versus external beam ... Section of the American Urological Association (MAAUA) Annual ... , "Comparing Relative Effectiveness of Cryosurgery and External ...
Breaking Biology Technology:Growing R&D Investments & Developments in Nanomaterials to Drive the Global Nanotechnology Market, According to New Report by Global Industry Analysts, Inc. 2Growing R&D Investments & Developments in Nanomaterials to Drive the Global Nanotechnology Market, According to New Report by Global Industry Analysts, Inc. 3Growing R&D Investments & Developments in Nanomaterials to Drive the Global Nanotechnology Market, According to New Report by Global Industry Analysts, Inc. 4Pfenex to Present at Upcoming Industry Conference on September 26 2Micro Market Monitor : Global Pre-packed Chromatography Columns 2HealthTronics Announces Data Comparing Cryotherapy Versus Radiation for Treating Prostate Cancer Poster Presented at the American Urological Association Regional Meeting 2
... March 31 For the first time, scientists have ... embryo) may be a potential new source of stem ... on February 12, 2009, in Blood , the ... on observations made by other scientists, our research team ...
... GENEVA, Switzerland, March 31 Viroblock SA ... VCCD Tech antiviral nasal spray,formulation is active ... Technology (VCCD Tech) inactivates enveloped,viruses during the ... envelopes. , The ...
... "personal genomics," featuring five of the most outstanding scientists, physicians and ... Bio-IT World Conference & Expo being held April 27-29 at the ... ... (PRWEB) March 31, 2009 -- A plenary panel discussion on the ...
Cached Biology Technology:Amniotic Fluid May Provide New Source of Stem Cells for Future Therapies 2Amniotic Fluid May Provide New Source of Stem Cells for Future Therapies 3Viroblock SA Reports Positive Results of Preclinical Studies in Antiviral Nasal Spray 2Keynote Panel at Bio-IT World Expo to Feature Five Leaders in the Field of "Personal Genomics" 2Keynote Panel at Bio-IT World Expo to Feature Five Leaders in the Field of "Personal Genomics" 3Keynote Panel at Bio-IT World Expo to Feature Five Leaders in the Field of "Personal Genomics" 4Keynote Panel at Bio-IT World Expo to Feature Five Leaders in the Field of "Personal Genomics" 5
(Date:9/18/2014)... into the Crimean-Congo hemorrhagic fever virus (CCHFV), a tick-borne ... similar to that caused by Ebolavirus, has identified new ... the potential to lead to novel targets for therapeutic ... reported in a paper published today in the journal ... the Texas Biomedical Research Institute and their colleagues, represents ...
(Date:9/18/2014)... matter how many times it,s demonstrated, it,s still ... , But by using a signaling system ... their behavior to suit their population. In short, ... present, and act accordingly. , Once the population ... change from innocuous to pathogenic, or from unhelpful ...
(Date:9/18/2014)... their colleagues have built the first smartphone app ... and behavioral trends. In other words, your smartphone ... you don,t -- and how that affects you. ... stress, depression and loneliness to their academic performance, ... for example, to monitor mental health, trigger ...
Breaking Biology News(10 mins):Research milestone in CCHF virus could help identify new treatments 2Researchers study vital 'on/off switches' that control when bacteria turn deadly 2Researchers study vital 'on/off switches' that control when bacteria turn deadly 3New Dartmouth smartphone app reveals users' mental health, performance, behavior 2New Dartmouth smartphone app reveals users' mental health, performance, behavior 3New Dartmouth smartphone app reveals users' mental health, performance, behavior 4
... the upcoming Acoustical Society of America (ASA) meeting in ... Wide pressroom even if they cannot attend in person. ... papers selected from among the 600 talks and posters, ... sound engineering, marine biology, medicine, meteorology, and music. ...
... ambitious European collaboration proposes to set up a new ... requisite skills for accelerating research into cardiovascular disease, the ... deaths, depending on the country. The European Vascular Biology ... conference in Lisbon in December 2007 with a specific ...
... for naming rights to a new owl butterfly species ... bid of $40,800, with proceeds benefiting continued research on ... George Austin and Andrew Warren discovered the new butterfly ... it in this weeks issue of the Bulletin of ...
Cached Biology News:Acoustics World Wide press room now open 2Acoustics World Wide press room now open 3Acoustics World Wide press room now open 4Proposal to step up cardiovascular disease research 2UF's new owl butterfly species naming rights auctioned for $40,800 2UF's new owl butterfly species naming rights auctioned for $40,800 3
...
... Kits synthesize RNA probes with specific activities ... High specific activity, single-stranded RNA probes are ... hybridization, and blot hybridizations. MAXIscript Kits can ... modest amounts of unlabeled RNA (2-4 g/20ul ...
Can be used for the quantitative recovery of small amounts of nucleic acids within dilute solutions. 5mg/ml...
... liquid controls for monitoring Aldolase tests. ... abnormal) with targeted manufacturing values at ... ± 3 IU/L. 30-day shelf ... 2-8 C. Level 1: 3 x ...
Biology Products: